Critical Comparison: Anebulo Pharmaceuticals (NASDAQ:ANEB) versus Stoke Therapeutics (NASDAQ:STOK)

Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) and Stoke Therapeutics (NASDAQ:STOK – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Profitability

This table compares Anebulo Pharmaceuticals and Stoke Therapeutics’ net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and price targets for Anebulo Pharmaceuticals and Stoke Therapeutics, as reported by MarketBeat.

Anebulo Pharmaceuticals currently has a consensus target price of $3.00, suggesting a potential upside of 142.91%. Stoke Therapeutics has a consensus target price of $34.78, suggesting a potential upside of 8.16%. Given Anebulo Pharmaceuticals’ higher probable upside, analysts clearly believe Anebulo Pharmaceuticals is more favorable than Stoke Therapeutics.

Institutional and Insider Ownership

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Stoke Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Anebulo Pharmaceuticals and Stoke Therapeutics”s gross revenue, earnings per share and valuation.

Anebulo Pharmaceuticals has higher earnings, but lower revenue than Stoke Therapeutics. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Anebulo Pharmaceuticals has a beta of -0.87, meaning that its stock price is 187% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.

Summary

Stoke Therapeutics beats Anebulo Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

About Anebulo Pharmaceuticals

(Get Free Report)

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.